PreprintCited by 372SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Open access

Voloch, Carolina M, Silva F, Ronaldo da, de Almeida, Luiz G P, Cardoso, Cynthia C, Brustolini, Otavio J., Gerber, Alexandra L, Guimarães, Ana Paula de C, Mariani, Diana, Costa, Raissa Mirella da, Ferreira, Orlando C., Covid19-UFRJ Workgroup, LNCC-Workgroup, Cavalcanti, Adriana Cony, Frauches, Thiago Silva, de Mello, Claudia Maria Braga, Galliez, Rafael Mello, Faffe, Débora Souza, Castiñeiras, Terezinha M P P, Tanuri, Amilcar, de Vasconcelos, Ana Tereza R·2020·Journal of Virology

DOI 10.1101/2020.12.23.20248598PMC PMC8139668

Preprint — published as 10.1128/jvi.00119-21 · Paper page

Open this paper in CoChat — free account

Abstract

In this study, we report the sequencing of 180 new viral genomes obtained from different municipalities of the state of Rio de Janeiro from April to December 2020. We identified a novel lineage of SARS-CoV-2, originated from B.1.1.28, distinguished by five single-nucleotide variants (SNVs): C100U, C28253U, G28628U, G28975U, and C29754U. The SNV G23012A (E484K), in the receptor-binding domain of Spike protein, was widely spread across the samples. This mutation was previously associated with escape from neutralizing antibodies against SARS-CoV-2. This novel lineage emerged in late July being first detected by us in late October and still mainly restricted to the capital of the state. However, as observed for other strains it can be rapidly spread in the state. The significant increase in the frequency of this lineage raises concerns about public health management and continuous need for genomic surveillance during the second wave of infections. Article Summary Line: We identified a novel circulating lineage of SARS-CoV-2 in the state of Rio de Janeiro Brazil originated from B.1.1.28 lineage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1101/2020.12.23.20248598

Cites

0 citation errors · 0 not checkable

Statistics

FIG 1 Phylogeny and timescale of P.2 lineage. (A) Maximum-likelihood tree of 1,377 SARS-CoV-2 genomes, including the 180 new Brazilian genomes generated in this work. We randomly sampled one genome/week/country from available samples in GISAID with collection dates ranging from May to November. Brazilian sequences with collection dates from May to November were all added to the data set (see Table S2). We ran IQTree 2.0.3 (10) under a general time-reversible (GTR) model of nucleotide substitution (11) with empirical base frequencies and invariant sites. Tips are colored according to their origin. Genomes generated from this work are red, other Brazilian genomes are blue, and genomes from other countries are not colored. Gray areas represent the three clades where Brazilian viruses are concentrated. The emergent lineage identified in this work, P.2, is in a dark-gray box and highlighted with red branches. The approximate likelihood ratio test (aLRT) support value for the branch holding P.2 monophyly is shown. (B) A time-scaled tree of clade II was estimated under a strict molecular clock in BEAST v.1.10.4 (12) using the GTR+I (11) nucleotide substitution model and assuming an exponential growth tree prior and a normal prior for the clock rate (mean = 8 × 10−4 and standard deviation = 0.1 × 10−5). The convergence of the Markov chain Monte Carlo chains, which were run at least for 50 million generations and sampled every 1,000th step, was inspected using Tracer v.1.7.1 (13). Maximum clade credibility (MCC) summary trees were generated using TreeAnnotator v.1.10.4 (12). Red circles in the tip nodes represent genomes generated in this work, and blue circles indicate other Brazilian samples. P.2 is identified by the red branches and highlighted in a gray box. The posterior probability of the branch holding P.2 monophyly is shown.CC BY · PubMed Central

FIG 2 Phylogeny of B.1.1.28 and its alias lineages (P.1 and P.2). Maximum-likelihood tree of 993 SARS-CoV-2 genomes. We downloaded all B.1.1.28, P.1, and P.2 high-coverage genomes available in GISAID on 11 February 2021. The phylogeny was estimated using IQTree 2.0.3 (10) under a GTR+F+R3 model chosen by ModelFinder. Brazilian genomes are not tip colored. Viruses from other countries are colored according to their geographical origin (dark blue, South America; light blue, North America; dark green, Europe; light green, Africa; brown, Asia; and orange, Oceania). Gray areas highlight P.1 and P.2 lineages. The aLRT support value for the branch holding P.1 and P.2 monophyly is shown. The tree is rooted with 3 B.1.1 genomes. The chart shows the single nucleotide polymorphisms (SNPs) that characterize P.1 and P.2 lineages.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era
Minh, B. Q., Schmidt, H. A., Chernomor, O., Schrempf, D., Woodhams, M. D., von Haeseler, A., & Lanfear, R. (2020) · Molecular Biology and Evolution · doi:10.1093/molbev/msaa015 · Cited by 16,873
A framework for variation discovery and genotyping using next-generation DNA sequencing data
DePristo, M. A., Banks, E., Poplin, R. E., Garimella, K. V., Maguire, J., Hartl, C., Philippakis, A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.806 · Cited by 11,457
Posterior summarization in Bayesian phylogenetics using tracer 1.7
Rambaut, A., Drummond, A. J., Xie, D., Baele, G., & Suchard, M. A. (2018) · Systematic Biology · doi:10.1093/sysbio/syy032 · Cited by 11,159
Application of Phylogenetic Networks in Evolutionary Studies
Huson, D. H., & Bryant, D. (2005) · Molecular Biology and Evolution · doi:10.1093/molbev/msj030 · Cited by 8,895
Dating of the human–ape splitting by a molecular clock of mitochondrial DNA.
Hasegawa, M., Kishino, H., & Yano, T.-A. (1985) · Journal of Molecular Evolution · doi:10.1007/bf02101694 · Cited by 8,687
adegenet : a R package for the multivariate analysis of genetic markers
Jombart, T. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn129 · Cited by 8,335
A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data
Li, H. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr509 · Cited by 6,454
Bayesian phylogenetic and phylodynamic data integration using BEAST 1.10
Suchard, M. A., Lemey, P., Baele, G., Ayres, D. L., Drummond, A. J., & Rambaut, A. (2018) · Virus Evolution · doi:10.1093/ve/vey016 · Cited by 3,749

Show all 27 references

Sorted by citations

SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528
Mechanisms of SARS-CoV-2 entry into cells
Jackson, C. B., Farzan, M., Chen, B., & Choe, H. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00418-x · Cited by 3,022
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Wang, Z., Schmidt, F., Weisblum, Y., Muecksch, F., Barnes, C. O., Finkin, S., Schaefer-Babajew, D., Cipolla, M., Gaebler, C., Lieberman, J. A., et al. (2021) · Nature · doi:10.1038/s41586-021-03324-6 · Cited by 1,343
Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.02.003 · Cited by 1,178
“In particular, our results predict that the emerging 20H/501Y.V2 and 20J/501Y.V3 viral lineages (originally identiﬁed in South Africa and Brazil, respectively) carrying the E484K mutation will have reduced susceptibility to neutralization by the polyclonal plasma antibodies of some individuals.”
Influential
Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
“7variant is associated with increased transmissibility,(9,10) and similar epidemiological observations have been reported for the SA and BR variants.(4,5) Themutations of greatest concern are present in the viral spike (S) protein and include notable mutations in the receptor-binding domain (RBD), the N-terminal domai…”
The SARS-CoV-2 main protease as drug target
Ullrich, S., & Nitsche, C. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127377 · Cited by 787
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C., Cho, A., Agudelo, M., Finkin, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24435-8 · Cited by 433
Testing at scale during the COVID-19 pandemic
Mercer, T. R., & Salit, M. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00360-w · Cited by 399
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans
Alter, G., Yu, J., Liu, J., Chandrashekar, A., Borducchi, E. N., Tostanoski, L. H., McMahan, K., Jacob-Dolan, C., Martinez, D. R., Chang, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03681-2 · Cited by 304
Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts
Kundu, R., Narean, J. S., Wang, L., Fenn, J., Pillay, T. D., Derqui, N., Conibear, E., Koycheva, A., Davies, M., Tolosa-Wright, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27674-x · Cited by 316
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285
“Chimeric viruses expressing the spoike genes of B.1.351 or B.1.1.28 were generated in the WA1/2020 backbone and have been described previously 42 .”
Influential
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19
van der Wijst, M. G. P., Vazquez, S. E., Hartoularos, G. C., Bastard, P., Grant, T., Bueno, R., Lee, D. S., Greenland, J. R., Sun, Y., Perez, R. K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abh2624 · Cited by 226
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies
Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · doi:10.1101/2020.12.31.425021 · Cited by 1,178
“The site where mutations tend to have the largest effect on binding and neutralization is E484, which unfortunately is a site where mutations are present in several emerging SARS-CoV-2 lineages (Tegally et al., 2020; Voloch et al., 2020).”
BackgroundInfluential
Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial
Cohen, M. S., Nirula, A., Mulligan, M. J., Novak, R. M., Marovich, M., Yen, C., Stemer, A., Mayer, S. M., Wohl, D., Brengle, B., et al. (2021) · JAMA · doi:10.1001/jama.2021.8828 · Cited by 193
Review of COVID-19 Variants and COVID-19 Vaccine Efficacy: What the Clinician Should Know?
Vasireddy, D., Vanaparthy, R., Mohan, G., Malayala, S. V., & Atluri, P. (2021) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4518 · Cited by 197
Experimental Evidence for Enhanced Receptor Binding by Rapidly Spreading SARS-CoV-2 Variants
Laffeber, C., de Koning, K., Kanaar, R., & Lebbink, J. H. G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167058 · Cited by 194
The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges
Malik, J. A., Ahmed, S., Aroosa, M., Shinde, M., Bender, O., Alshammari, F., Ansari, M., & Anwar, S. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.12.014 · Cited by 206
Molecular basis of receptor binding and antibody neutralization of Omicron
Qin, H., Han, W., Li, J., Xu, S., Wang, Y., Xu, C., Li, Z., Wang, Y., Zhang, C., Huang, Z. W., et al. (2022) · Nature · doi:10.1038/s41586-022-04581-9 · Cited by 198
Emerging SARS-CoV-2 variants expand species tropism to murines
Shuai, H., Chan, J. F., Yuen, T. T., Yoon, C., Hu, J., Wen, L., Hu, B., Yang, D., Wang, Y., Hou, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103643 · Cited by 166
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Cai, Y., Zhang, J., Xiao, T., Lavine, C. L., Rawson, S., Peng, H., Zhu, H., Anand, K., Tong, P., Gautam, A. K., et al. (2021) · Science · doi:10.1126/science.abi9745 · Cited by 222
“28 lineage in Brazil within a period of several months (3-5).”
Background
Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees
(2021) · doi:10.1101/2021.02.27.433180 · Cited by 706
“351, P.1 and the CAL.20C variants.”
Influential
Structural basis for SARS-CoV-2 Delta variant recognition of ACE2 receptor and broadly neutralizing antibodies
Wang, Y., Liu, C., Zhang, C., Wang, Y., Qin, H., Xu, S., Li, Z., Yang, Y. P., Huang, Z. W., & Cong, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-28528-w · Cited by 175
Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines
Cao, Y., Yisimayi, A., Bai, Y., Huang, W., Li, X., Zhang, Z., Yuan, T., An, R., Wang, J., Xiao, T., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00514-9 · Cited by 140
“V3, is discovered and announced in January 2021 in Brazil.(3) 501Y.”
Background
Ongoing global and regional adaptive evolution of SARS-CoV-2
Rochman, N. D., Wolf, Y. I., Faure, G., Mutz, P., Zhang, F., & Koonin, E. V. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2104241118 · Cited by 243
Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
Focosi, D., & Maggi, F. (2021) · Reviews in Medical Virology · doi:10.1002/rmv.2231 · Cited by 150
Covid-19: What new variants are emerging and how are they being investigated?
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n158 · Cited by 150
Phylogenetic and phylodynamic approaches to understanding and combating the early SARS-CoV-2 pandemic
Attwood, S. W., Hill, S. C., Aanensen, D. M., Connor, T. R., & Pybus, O. G. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00483-8 · Cited by 154
Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677Preprint
Hodcroft, E. B., Domman, D., Snyder, D. J., Oguntuyo, K. Y., Diest, M. V., Densmore, K. H., Schwalm, K. C., Femling, J., Carroll, J. L., Scott, R. S., et al. (2021) · medRxiv · doi:10.1101/2021.02.12.21251658 · Cited by 110
Evolutionary trajectory of SARS-CoV-2 and emerging variants
Singh, J., Pandit, P., McArthur, A. G., Banerjee, A., & Mossman, K. L. (2021) · Virology Journal · doi:10.1186/s12985-021-01633-w · Cited by 150
First and second COVID-19 waves in Brazil: A cross-sectional study of patients’ characteristics related to hospitalization and in-hospital mortality
Zeiser, F. A., Donida, B., da Costa, C. A., Ramos, G. D. O., Scherer, J. N., Barcellos, N. T., Alegretti, A. P., Ikeda, M. L. R., Müller, A. P. W. C., Bohn, H. C., et al. (2021) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2021.100107 · Cited by 141
Ongoing Global and Regional Adaptive Evolution of SARS-CoV-2Preprint
Rochman, N. D., Wolf, Y., Faure, G., et al. (2020) · bioRxiv · doi:10.1101/2020.10.12.336644 · Cited by 123
Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B.1.351 variant in South Africa
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · doi:10.1101/2021.02.10.21251247 · Cited by 1,257
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 149
Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil
Francisco, R. D. S., Benites, L. F., Lamarca, A. P., de Almeida, L. G. P., Hansen, A. W., Gularte, J. S., Demoliner, M., Gerber, A. L., Guimarães, A. P. D. C., Eisen, A. K. A., et al. (2021) · Virus Research · doi:10.1016/j.virusres.2021.198345 · Cited by 110
“Next-generation sequencing (NGS) data was processed using a bioinformatic pipeline described in our previous study (Voloch et al., 2020a).”
InfluentialSelf-citation
New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge
Islam, S., Islam, T., & Islam, M. R. (2022) · Clinical Pathology · doi:10.1177/2632010x221075584 · Cited by 133
COVID-19 Diagnosis: A Comprehensive Review of the RT-qPCR Method for Detection of SARS-CoV-2
Dutta, D., Naiyer, S., Mansuri, S., Soni, N., Singh, V., Bhat, K. H., Singh, N., Arora, G., & Mansuri, M. S. (2022) · Diagnostics · doi:10.3390/diagnostics12061503 · Cited by 151
Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100405 · Cited by 121
The Emerging Concern and Interest SARS-CoV-2 Variants
Janik, E., Niemcewicz, M., Podogrocki, M., Majsterek, I., & Bijak, M. (2021) · Pathogens · doi:10.3390/pathogens10060633 · Cited by 113
Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil
Giovanetti, M., Slavov, S. N., Fonseca, V., Wilkinson, E., Tegally, H., Patané, J. S. L., Viala, V. L., San, J. E., Rodrigues, E. S., Santos, E. V., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01191-z · Cited by 109
An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines
Hillary, V. E., & Ceasar, S. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13952 · Cited by 121
Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants
Cai, Y., Zhang, J., Xiao, T., et al. (2021) · bioRxiv · doi:10.1101/2021.04.13.439709 · Cited by 92
Current status of therapeutic monoclonal antibodies against SARS-CoV-2
Kumar, S., Chandele, A., & Sharma, A. K. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009885 · Cited by 104
“CP, cytoplasmic tail; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; mAb, monoclonal antibody; NTD, N-terminal domain; PDB, Protein Data Bank; RBD, receptor-binding domain; RBM, receptor-binding motif; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; SP, signal peptide; TM, transmembrane d…”
BackgroundInfluential
The COVID-19 Pandemic: a Threat to Antimicrobial Resistance Containment
Founou, R. C., Blocker, A., Noubom, M., Tsayem, C., Choukem, S. P., van Dongen, M. B. M., & Founou, L. L. (2021) · Future Science OA · doi:10.2144/fsoa-2021-0012 · Cited by 108
“1 variant exhibiting around 35 mutations with 17 amino acid changes was reported in Brazil on 12 January 2021 [24].”
Background
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Chiu, H.-P., Stevens, C. S., Vilardo, A. E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24909-9 · Cited by 141
Obesity and its impact on COVID-19
de Leeuw, A. J. M., Luttikhuis, M. A. M. O., Wellen, A. C., Müller, C., & Calkhoven, C. F. (2021) · Journal of Molecular Medicine · doi:10.1007/s00109-021-02072-4 · Cited by 115
Genomic Evidence of a Sars-Cov-2 Reinfection Case With E484K Spike Mutation in BrazilPreprint
Nonaka, C. K. V., Franco, M. M., Gräf, T., Mendes, A. V. A., Aguiar, R. S., Giovanetti, M., & Souza, B. S. D. F. (2021) · Preprints.org · doi:10.20944/preprints202101.0132.v1 · Cited by 64
“Molecular characterization of a COVID-19 reinfection case in Salvador, Bahia state, Northeast Brazil.”
BackgroundInfluential
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Chakraborty, S., Mallajosyula, V. V. A., Tato, C. M., Tan, G. S., & Wang, T. T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.014 · Cited by 90
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Modelling and optimal control of multi strain epidemics, with application to COVID-19
Arruda, E. F., Das, S. S., Dias, C. M., & Pastore, D. H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0257512 · Cited by 85
Differential interactions between human ACE2 and spike RBD of SARS-CoV-2 variants of concern
Kim, S., Liu, Y., Lei, Z., et al. (2021) · bioRxiv · doi:10.1101/2021.07.23.453598 · Cited by 78
Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19
Heida, R., Hinrichs, W. L. J., & Frijlink, H. W. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1903878 · Cited by 96
Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease
Case, J. B., Chen, R. E., Cao, L., Ying, B., Winkler, E. S., Johnson, M., Goreshnik, I., Pham, M. N., Shrihari, S., Kafai, N. M., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.008 · Cited by 73
E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil
Ferrareze, P. A. G., Franceschi, V. B., Mayer, A. D. M., Caldana, G. D., Zimerman, R. A., & Thompson, C. E. (2021) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2021.104941 · Cited by 82
Neutralization capacity of antibodies elicited through homologous or heterologous infection or vaccination against SARS-CoV-2 VOCs
Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 86
Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses
Nathan, A., Rossin, E. J., Kaseke, C., Park, R. J.-H., Khatri, A., Koundakjian, D., Urbach, J. M., Singh, N. K., Bashirova, A. A., Tano-Menka, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.029 · Cited by 84
“…Polack et al., 2020; Sadoff et al., 2021), the emergence of the B.1.1.7 alpha (Tang et al., 2020), B.1.351 beta (Tegally et al., 2021), P.1 gamma (Voloch et al., 2020), and B.1.617.2 delta variants (Cherian et al., 2021) has raised substantial new concerns due to their increased transmissibility…”
Influential
Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK
Toovey, O. T. R., Harvey, K. N., Bird, P. W., & Tang, J. W.-T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.025 · Cited by 74
One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar
Benslimane, F. M., Al-Khatib, H. A., Al-Jamal, O., Albatesh, D., Boughattas, S., Ahmed, A. A., Bensaad, M., Younuskunju, S., Mohamoud, Y. A., Badr, M. A., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.768883 · Cited by 66
“Only a few samples -collected in March 2021- intermixed with genomes from Greece, South Africa, and the USA (Figure 5B).”
BackgroundInfluential
Emergence and spread of a SARS-CoV-2 lineage A variant (A.23.1) with altered spike protein in Uganda
Bugembe, D. L., Phan, M. V. T., Ssewanyana, I., Semanda, P., Nansumba, H., Dhaala, B., Nabadda, S. N., O’Toole, Á., Rambaut, A., Kaleebu, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00933-9 · Cited by 104
Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro
Fred, S. M., Kuivanen, S. H., Uğurlu, H., Casarotto, P. C., Levanov, L., Saksela, K., Vapalahti, O., & Ċastrén, E. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.755600 · Cited by 67
“…of an Emergent SARS-CoV-2 Lineage in Manaus, 2021; Phylogenetic Relationship of SARS-CoV-2 Sequences from Amazonas with Emerging Brazilian Variants Harboring Mutations E484K and N501Y in the Spike Protein - SARS-CoV-2 Coronavirus /NCoV-2019 Genomic Epidemiology, 2021; Voloch et al., 2020).”
Conformational dynamics of the Beta and Kappa SARS-CoV-2 spike proteins and their complexes with ACE2 receptor revealed by cryo-EM
Wang, Y., Xu, C., Wang, Y., Qin, H., Zhang, C., Li, Z., Xu, S., Zuo, Q., Liu, C., Huang, Z. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27350-0 · Cited by 85
Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · doi:10.1101/2021.01.27.428529 · Cited by 55
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 99
RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact
Vega‐Magaña, N., Sánchez-Sánchez, R., Hernández‐Bello, J., Venancio-Landeros, A. A., Rodríguez, M. P., Vega-Zepeda, R. A., Galindo-Ornelas, B., Díaz-Sánchez, M., García‐Chagollán, M., Ojeda, G. M., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.672562 · Cited by 67
Intra-host evolution during SARS-CoV-2 prolonged infection
Voloch, C. M., Francisco, R. D. S., de Almeida, L. G. P., Brustolini, O. J. B., Cardoso, C. C., Gerber, A. L., Guimarães, A. P. D. C., Leitão, I. D. C., Mariani, D., Ota, V. A., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab078 · Cited by 99
Self-citation
SARS-CoV-2 new variants: Characteristic features and impact on the efficacy of different vaccines
Khan, A., Khan, T., Ali, S., Aftab, S., Wang, Y., Wang, Q., Khan, M., Suleman, M., Ali, S., Heng, W., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112176 · Cited by 75
Diagnosis and prediction of COVID-19 severity: can biochemical tests and machine learning be used as prognostic indicators?
Cobre, A. D. F., Stremel, D. P., Noleto, G. R., Fachi, M. M., Surek, M., Wiens, A., Tonin, F. S., & Pontarolo, R. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104531 · Cited by 63
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodiesPreprint
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y., Huey-Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P., Nussenzweig, M., et al. (2021) · bioRxiv · doi:10.1101/2021.04.23.441195 · Cited by 54
“…SARS-CoV-2, SARS-CoV-2 RBD mutants, SARS-CoV-2 variants (Annavajhala et al., 2021; Faria et al., 2021; Rambaut et al., 2020; Tegally et al., 2020; Voloch et al., 2020; West et al., 2021; Zhang et al., 2021), and sarbecovirus strains known to infect human ACE2-expressing target cells (SARS-CoV-2,…”
Influential
Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro
Zeng, L., Liu, Y., Wrynla, X. H., Abbott, T. R., Han, M., Zhu, Y., Chemparathy, A., Lin, X., Chen, X., Wang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30546-7 · Cited by 53
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens, S. A. C., Folegatti, P. M., Emary, K. R. W., Weckx, L. Y., Ratcliff, J., Bibi, S., Mendes, A. V. A., Milan, E. P., Pittella, A. M., Schwarzbold, A. V., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25982-w · Cited by 57
CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern
Liang, Y., Lin, H., Zou, L., Zhao, J., Li, B., Wang, H., Lu, J., Sun, J., Yang, X., Deng, X., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01017-21 · Cited by 78
Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11
Fédry, J., Hurdiss, D. L., Wang, C., Li, W., Obal, G., Drulyte, I., Du, W., Howes, S. C., van Kuppeveld, F. J. M., Förster, F. G., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf5632 · Cited by 54
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants
Rothenberger, S., Hurdiss, D. L., Walser, M., Malvezzi, F., Mayor, J., Ryter, S., Moreno, H., Liechti, N., Bosshart, A., Iss, C., et al. (2022) · Nature Biotechnology · doi:10.1038/s41587-022-01382-3 · Cited by 75
Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Gupta, D., Sharma, P., Singh, M., Kumar, M., Ethayathulla, A. S., & Kaur, P. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04008-0 · Cited by 56
“It was first reported in the state of Rio de Janeiro, Brazil [63].”
Background
Bioinformatics analysis of the differences in the binding profile of the wild-type and mutants of the SARS-CoV-2 spike protein variants with the ACE2 receptor
Suleman, M., Yousafi, Q., Ali, J., Ali, S. S., Hussain, Z., Ali, S., Waseem, M., Iqbal, A., Ahmad, S., Khan, A., et al. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104936 · Cited by 49
“Efforts to disclose the genomic organization of SARS-CoV-2 have revealed that the virus consists of sixteen nonstructural proteins (NSP1 – NSP16) and four structural proteins (S protein, E protein, N protein, and M protein) [17,18].”
The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein
Resende, P. C., Naveca, F. G., Lins, R. D., Dezordi, F. Z., Ferraz, M. V. F., Moreira, E. G., Coêlho, D. F., Motta, F. C., Paixão, A. C. D., Appolinario, L., et al. (2021) · Virus Evolution · doi:10.1093/ve/veab069 · Cited by 47
Assessment of SARS-CoV-2 Genome Sequencing: Quality Criteria and Low-Frequency Variants
Jacot, D., Pillonel, T., Greub, G., & Bertelli, C. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00944-21 · Cited by 43
A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection
Liu, H., Yuan, M., Huang, D., Bangaru, S., Zhao, F., Lee, C.-C. D., Peng, L., Barman, S., Zhu, X., Nemazee, D. A., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.005 · Cited by 58
“…mutations in both human and mink populations give rise to concerns about viral escape from current vaccines and therapeutics in development (Andreano et al., 2020; Greaney et al., 2021a; Kemp et al., 2021; Mallapaty, 2020; Oude Munnink et al., 2021; Tegally et al., 2021; Voloch et al., 2021).”
Background
Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodiesPreprint
Greaney, A. J., Starr, T. N., Barnes, C., et al. (2021) · bioRxiv · doi:10.1101/2021.03.17.435863 · Cited by 45
A Potential SARS-CoV-2 Variant of Interest (VOI) Harboring Mutation E484K in the Spike Protein Was Identified within Lineage B.1.1.33 Circulating in Brazil
Resende, P. C., Gräf, T., Paixão, A. C. D., Appolinario, L., Lopes, R. S., Mendonça, A. C. D. F., da Rocha, A. S. B., Motta, F. C., Neto, L. G. L., Khouri, R., et al. (2021) · Viruses · doi:10.3390/v13050724 · Cited by 45
“2, first described in samples from October 2020 in the state of Rio de Janeiro, was distinguished by the presence of the S:E484K mutation in RBD and other four lineage-defining mutations outside the S protein [6].”
BackgroundSelf-citation
A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemicPreprint
Bugembe, D., V.T.Phan, M., Ssewanyana, I., et al. (2021) · medRxiv · doi:10.1101/2021.02.08.21251393 · Cited by 45
“1 (7) ) and applied the 250 same profileHMM analysis.”
Method
Sequence Analysis of 20,453 Severe Acute Respiratory Syndrome Coronavirus 2 Genomes from the Houston Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern
Long, S. W., Olsen, R. J., Christensen, P. A., Subedi, S., Olson, R., Davis, J. J., Saavedra, M. O., Yerramilli, P., Pruitt, L., Reppond, K., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.004 · Cited by 46
Estimation of Secondary Household Attack Rates for Emergent Spike L452R Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants Detected by Genomic Surveillance at a Community-Based Testing Site in San Francisco
Peng, J., Liu, J., Mann, S. A., Mitchell, A. M., Laurie, M. T., Sunshine, S., Pilarowski, G., Ayscue, P., Kistler, A., Vanaerschot, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab283 · Cited by 41
Dynamic Profiling of Binding and Allosteric Propensities of the SARS-CoV-2 Spike Protein with Different Classes of Antibodies: Mutational and Perturbation-Based Scanning Reveal Allosteric Duality of Functionally Adaptable Hotspots
Verkhivker, G. M., Agajanian, S., Oztas, D., et al. (2021) · bioRxiv · doi:10.1101/2021.04.13.439743 · Cited by 42
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
“For example, a B.1.526 sub-lineage carrying E484K in recent weeks has expanded more rapidly than B.1.1.7 (Annavajhala et al. , 2021; West et al. , 2021), which may be indicative of the ability of S: E484K variants to penetrate herd immunity.”
Influential
Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil
Martins, A. F., Zavascki, A. P., Wink, P. L., Volpato, F. C. Z., Monteiro, F. L., Rosset, C., de Paris, F., Ramos, Á., & Barth, A. L. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.12.2100276 · Cited by 60
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 in nonhuman primates following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccinationPreprint
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 29
Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants
Upadhyay, V., Lucas, A., Panja, S., Miyauchi, R., & Mallela, K. M. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101208 · Cited by 44
ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology
Gawish, R., Starkl, P. M., Pimenov, L., Hladik, A., Lakovits, K., Oberndorfer, F., Cronin, S. J., Ohradanova‐Repic, A., Wirnsberger, G., Agerer, B., et al. (2022) · eLife · doi:10.7554/elife.74623 · Cited by 61
“Upon adaptation to humans, SARS-CoV-2 evolution gave rise to multiple variants including novel SARS-CoV-2 variants of concern (VOCs), characterized by increased transmissibility and/or virulence, or reduced effectiveness of countermeasures such as vaccinations or antibody therapies (WHO, 2021a).”
BackgroundResultInfluential
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38
“residues in the spike glycoprotein (6-8), has resulted in the continued implementation 74 of stringent public health measures to control infection in many parts of the world.”
Background
Genomic surveillance of SARS-CoV-2 tracks early interstate transmission of P.1 lineage and diversification within P.2 clade in Brazil
Lamarca, A. P., de Almeida, L. G. P., Francisco, R. D. S., Agnez‐Lima, L. F., Scortecci, K. C., Perez, V. P., Brustolini, O. J. B., Sousa, E. S. S., Secco, D., Santos, Â., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009835 · Cited by 35
Self-citation
Coronavirus Disease 2019 (COVID-19) Diagnostic Tools: A Focus on Detection Technologies and Limitations
Qasem, A., Shaw, A. M., Elkamel, E., & Naser, S. A. (2021) · Current Issues in Molecular Biology · doi:10.3390/cimb43020053 · Cited by 43
Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
Kurt, F. G. Ö., Lepper, A., Gerhards, C., Roemer, M., Lasser, S., Arkhypov, I., Bitsch, R., Bugert, P., Altevogt, P., Gouttefangeas, C., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012526 · Cited by 48
“Emergence of different variants has generated concern about the effectiveness of immunity after vaccination (18, 19).”
Background
Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation
Meyers, L. M., Gutiérrez, A. H., Boyle, C., Terry, F. E., McGonnigal, B., Salazar, A. Μ., Princiotta, M. F., Martin, W. D., Groot, A. S. D., & Moise, L. (2021) · npj Vaccines · doi:10.1038/s41541-021-00331-6 · Cited by 44
50 Years of structural immunology
Wilson, I. A., & Stanfield, R. L. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100745 · Cited by 44
Novel SARS-CoV-2/COVID-19: Origin, pathogenesis, genes and genetic variations, immune responses and phylogenetic analysis
Junejo, Y., Özaslan, M., Safdar, M., Khailany, R. A., Rehman, S. U., Yousaf, W., & Khan, M. A. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100752 · Cited by 50
“All non-coding mutations are within 3′UTR or 5′UTR regions that have C>T changes (Rozhgar et al., 2020).”
A simple reverse genetics method to generate recombinant coronaviruses
Mélade, J., Piorkowski, G., Touret, F., Fourié, T., Driouich, J., Cochin, M., Bouzidi, H. S., Coutard, B., Nougaırède, A., & de Lamballerie, X. N. (2022) · EMBO Reports · doi:10.15252/embr.202153820 · Cited by 44
Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies : Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations
Verkhivker, G. M., Agajanian, S., Oztas, D., et al. (2021) · bioRxiv · doi:10.1101/2021.02.21.432165 · Cited by 36
Genomic epidemiology of SARS-CoV-2 in Esteio, Rio Grande do Sul, Brazil
Franceschi, V. B., Caldana, G. D., Mayer, A. D. M., Cybis, G. B., Neves, C. A. M., Ferrareze, P. A. G., Demoliner, M., de Almeida, P. R., Gularte, J. S., Hansen, A. W., et al. (2021) · BMC Genomics · doi:10.1186/s12864-021-07708-w · Cited by 34
“Phylodynamics inferences pointed that this lineage emerged in early July, approximately four months before the detection of its first genomes [53].”

Authors: Voloch, C. M., Silva F, R. D., de Almeida, L. G. P., Cardoso, C. C., Brustolini, O. J., Gerber, A. L., Guimarães, A. P. D. C., Mariani, D., Costa, R. M. D., Ferreira, O. C., Workgroup, C.-U., LNCC-Workgroup, Cavalcanti, A. C., Frauches, T. S., de Mello, C. M. B., Galliez, R. M., Faffe, D. S., Castiñeiras, T. M. P. P., Tanuri, A., & de Vasconcelos, A. T. R.
Affiliations: Universidade Federal do Rio de Janeiro (BR)
Laboratório Nacional de Computação Científica (BR)
Secretaria de Estado de Saúde do Rio de Janeiro (BR)
ORCID: Voloch, Carolina M
Silva F, Ronaldo da
de Almeida, Luiz G P
Cardoso, Cynthia C
Brustolini, Otavio J.
Gerber, Alexandra L
Guimarães, Ana Paula de C
Mariani, Diana
Ferreira, Orlando C.
Galliez, Rafael Mello
Faffe, Débora Souza
Castiñeiras, Terezinha M P P
Tanuri, Amilcar
de Vasconcelos, Ana Tereza R
Venue: Journal of Virology
Publisher: openRxiv
Published: 2020-12-26
Volume: 95
Issue: 10
ISSN: 0022-538X (ISSN-L)
DOI: 10.1101/2020.12.23.20248598
PMC: PMC8139668
OpenAlex: W3135409471
Cited by: 372
References: 31
Citations by year: 2026: 5 · 2025: 8 · 2024: 25 · 2023: 34 · 2022: 93 · 2021: 206
FWCI: 28.43
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Journal of Virology (publishedVersion, cc-by)
medRxiv (acceptedVersion)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: Ministério da Ciência, Tecnologia e Inovação (01.20.0029.000462/20, 303170/2017-4, 404096/2020-4)
Conselho Nacional de Desenvolvimento Científico e Tecnológico (= 404,096/2020–4, # 303170/2017-4)
Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (E-26/202.791/2019, E-26/010.002278/2019, E-26/, E‐26/210.178/2020, E-26/210, =E-26/210.179/2020, E-26/202.903/20, E-26/010.002434/2019)
Financiadora de Estudos e Projetos (01.20.0029.000462/20)
Instituto Serrapilheira
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
Keywords: SARS-CoV-2, novel viral lineages, genomic profiling, phylogenetic analysis, genetic divergence, Rio de Janeiro, COVID-19 pandemic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks